Caribou Biosciences (CRBU) EBITDA Yield: History & Chart

Caribou Biosciences, Inc.(CRBU)

Biotechnology · Berkeley, CA

$1.20+0.01 (+0.42%)

Delayed quote: Oct 6, 2026, 9:40 AM EDT

About Caribou Biosciences, Inc.

Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.

Berkeley, CA

97 employees

cariboubio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Rachel E. Haurwitz

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Caribou Biosciences, Inc. (CRBU)	$118.52M	N/A	N/A	N/A	N/A
TuHURA Biosciences, Inc. (HURA)vs ›	$119.09M	N/A	N/A	N/A	N/A
Genelux Corporation (GNLX)vs ›	$117.03M	N/A	N/A	N/A	N/A
Foghorn Therapeutics Inc. (FHTX)vs ›	$116.84M	N/A	N/A	N/A	N/A
Insight Molecular Diagnostics Inc. (IMDX)vs ›	$120.80M	N/A	N/A	N/A	N/A
Aardvark Therapeutics, Inc. Common Stock (AARD)vs ›	$115.66M	N/A	N/A	N/A	N/A
LENZ Therapeutics, Inc. (LENZ)vs ›	$114.76M	N/A	N/A	N/A	N/A
Coya Therapeutics, Inc. (COYA)vs ›	$114.47M	N/A	N/A	N/A	N/A
enGene Holdings Inc. (ENGN)vs ›	$123.26M	N/A	N/A	N/A	N/A
Black Diamond Therapeutics, Inc. (BDTX)vs ›	$111.58M	N/A	6.77%	6.77%	6.77%

NAME

MARKET CAP

EBITDA YIELD

TTM

Caribou Biosciences, Inc. (CRBU)

$118.52M

N/A

TuHURA Biosciences, Inc. (HURA)vs ›

$119.09M

N/A

Genelux Corporation (GNLX)vs ›

$117.03M

N/A

Foghorn Therapeutics Inc. (FHTX)vs ›

$116.84M

N/A

Insight Molecular Diagnostics Inc. (IMDX)vs ›

$120.80M

N/A

Aardvark Therapeutics, Inc. Common Stock (AARD)vs ›

$115.66M

N/A

LENZ Therapeutics, Inc. (LENZ)vs ›

$114.76M

N/A

Coya Therapeutics, Inc. (COYA)vs ›

$114.47M

N/A

enGene Holdings Inc. (ENGN)vs ›

$123.26M

N/A

Black Diamond Therapeutics, Inc. (BDTX)vs ›

$111.58M

N/A

6.77%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

CRBU EBITDA Yield Metrics

CRBU Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics